Zhu Hua, Wu Hao, Liu Xiuping, Evans Brad R, Medina Daniel J, Liu Chang-Gong, Yang Jin-Ming
Department of Pharmacology, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, NJ 08903, United States.
Biochem Pharmacol. 2008 Sep 1;76(5):582-8. doi: 10.1016/j.bcp.2008.06.007. Epub 2008 Jun 24.
MicroRNAs are short non-coding RNA molecules able to affect stability and/or translation of mRNA, thereby regulating the expression of genes involved in many biological processes. We report here that microRNAs miR-27a and miR-451 are involved in activating the expression of P-glycoprotein, the MDR1 gene product that confers cancer cell resistance to a broad range of chemotherapeutics. We showed that expressions of miR-27a and miR-451 were up-regulated in multidrug resistant (MDR) cancer cell lines A2780DX5 and KB-V1, as compared with their parental lines A2780 and KB-3-1. Treatment of A2780DX5 cells with the antagomirs of miR-27a or miR-451 decreased the expression of P-glycoprotein and MDR1 mRNA. In contrast, the mimics of miR-27a and miR-451 increased MDR1 expression in the parental cells A2780. The sensitivity to and intracellular accumulation of cytotoxic drugs that are transported by P-glycoprotein were enhanced by the treatment with the antagomirs of miR-27a or miR-451. Our results demonstrate for the first time the roles of microRNAs in the regulation of drug resistance mediated by MDR1/P-glycoprotein, and suggest the potential for targeting miR-27a and miR-451 as a therapeutic strategy for modulating MDR in cancer cells.
微小RNA是短的非编码RNA分子,能够影响mRNA的稳定性和/或翻译,从而调节参与许多生物过程的基因的表达。我们在此报告,微小RNA miR-27a和miR-451参与激活P-糖蛋白的表达,P-糖蛋白是MDR1基因的产物,可赋予癌细胞对多种化疗药物的抗性。我们发现,与它们的亲本细胞系A2780和KB-3-1相比,多药耐药(MDR)癌细胞系A2780DX5和KB-V1中miR-27a和miR-451的表达上调。用miR-27a或miR-451的拮抗剂处理A2780DX5细胞会降低P-糖蛋白和MDR1 mRNA的表达。相反,miR-27a和miR-451的模拟物增加了亲本细胞A2780中MDR1的表达。用miR-27a或miR-451的拮抗剂处理可增强对由P-糖蛋白转运的细胞毒性药物的敏感性和细胞内积累。我们的结果首次证明了微小RNA在由MDR1/P-糖蛋白介导的耐药性调节中的作用,并表明靶向miR-27a和miR-451作为调节癌细胞中MDR的治疗策略的潜力。